No Data
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $50
H.C. Wainwright analyst Mitchell Kapoor maintains $Halozyme Therapeutics(HALO.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate o
Halozyme Therapeutics(HALO.US) Officer Sells US$905.48K in Common Stock
$Halozyme Therapeutics(HALO.US)$ Officer LaBarre Michael J. sold 20,000 shares of common stock on May 21, 22, 2024 at an average price of $45.274 for a total value of $905.48K.Source: Announcement Wha
Halozyme Therapeutics Insider Sold Shares Worth $905,480, According to a Recent SEC Filing
Michael J. Labarre, Senior Vice President, Chief Technical Officer, on May 21, 2024, sold 20,000 shares in Halozyme Therapeutics (HALO) for $905,480. Following the Form 4 filing with the SEC, Labarre
Form 144 | Halozyme Therapeutics(HALO.US) Officer Proposes to Sell 453.84K in Common Stocks
SEC FILLINGS DISCLOSED/ May 22, $Halozyme Therapeutics(HALO.US)$ Officer MICHAEL LABARRE intends to sell 10,000 shares of its common stock on May 22, with a total market value of approximately $453.84
Form 144 | Halozyme Therapeutics(HALO.US) Officer Proposes to Sell 451.64K in Common Stocks
SEC FILLINGS DISCLOSED/ May 21, $Halozyme Therapeutics(HALO.US)$ Officer MICHAEL LABARRE intends to sell 10,000 shares of its common stock on May 21, with a total market value of approximately $451.64
Halozyme Discloses That Bristol Myers Squibb Received Updated Action Date From U.S. FDA For Subcutaneous Nivolumab Co-Formulated With ENHANZE (Halozyme's Proprietary Recombinant Human Hyaluronidase Enzyme); The Updated Goal Date Is December 29, 2024
Halozyme announced that Bristol Myers Squibb was reassigned a Prescription Drug User Fee Act goal date from the U.S. Food and Drug Administration for their Biologics License Application for the subcut